KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Research / 2021 / Cilt: 28 - Sayı: 7

Therapeutic plasma exchange in neuroimmunologicdisease: 60 patients experience

Azize Esra GÜRSOY
Ferda İlgen USLU
Sayfa
1277–1283
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The duration of hospitalization was 28.1 (±13.1) in group 1 and 32.9 (±19) days in group 2 (p: 0.01).Conclusion: Our experience has supported that TPE is a safe and effective treatment option for a wide range of antibody-related neurological disorders, especially if it is the first treatment option.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: We aimed to determine the results, safety, and applicability of therapeutic plasma exchange (TPE) in neurological diseases.Materials and Methods: We performed a retrospective analysis in between 2014-2019.
📊
Temel Bulgular & Veri:In the evaluation of response to treatment (RT), patients were divided into 4 groups: full recovery (RT1), partial recovery (RT2), stationary or worse (RT3), exitus (RT4).
💡
Sonuç & Katkı:The duration of hospitalization was 28.1 (±13.1) in group 1 and 32.9 (±19) days in group 2 (p: 0.01).Conclusion: Our experience has supported that TPE is a safe and effective treatment option for a wide range of antibody-related neurological disorders, especially if it is the first treatment option.
🔬Tür:Araştırma Makalesi
📍Kapsam:2014-2019 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Aim: We aimed to determine the results, safety, and applicability of therapeutic plasma exchange (TPE) in neurological diseases.Materials and Methods: We performed a retrospective analysis in between 2014-2019. In the evaluation of response to treatment (RT), patients were divided into 4 groups: full recovery (RT1), partial recovery (RT2), stationary or worse (RT3), exitus (RT4). TPE treatment was evaluated effective in patients with RT1 and RT2. Patients' data were compared between group 1 (TPE as first line treatment) and group 2 (TPE as additional therapy).Results: TPE procedure was applied to 199 patients, 1330 times. Sixty neurological patients (mean age 51.5±17.05; 24 female) underwent 356 TPE procedures on average 6.2 sessions. After TPE, functional status was RT1:3, RT2:19, RT3:28, RT:10. TPE was an effective treatment in 36.6% of patients.Disease distribution Guillain Barre syndrome (n:26), myasthenia gravis (n:8), autoimmune encephalitis (n:6), neuromyelitis optica (n:5), transverse myelitis (n:5), vasculitis (n:3), chronic demyelinating inflammatory polyneuropathy (n:2), multiple sclerosis (n:2), Morvan syndrome (n:1), myeloradiculitis (n:1) and polymyositis (n:1). 7 patients (11.6%) were included in group 1 and 53 patients were in group 2. TPE was started after 9.7 days (±6.9) due to insufficient response. Complications were found in 6 patients (10%). The duration of hospitalization was 28.1 (±13.1) in group 1 and 32.9 (±19) days in group 2 (p: 0.01).Conclusion: Our experience has supported that TPE is a safe and effective treatment option for a wide range of antibody-related neurological disorders, especially if it is the first treatment option.

🔖

Bu Makaleye Atıf Yap

GÜRSOY, A. E., USLU, F. İ. (2022). Therapeutic plasma exchange in neuroimmunologicdisease: 60 patients experience. Annals of Medical Research, Cilt: 28 - Sayı: 7, 1277–1283. https://ajindex.com/articles/445710

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Ranganathan D, John GT. Therapeutic Plasma Exchange in Renal Disorders. Indian J Nephrol 2019,29:151-9
  2. Pusey CD, Levy JB. Plasmapheresis in immunologic renal disease. Blood Purif 2012;33:190-8
  3. Huestis DW, Corrigan JJ, Johnson HV. Leukapheresis of a five-year-old girl with chronic granulocytic leukemia. Transfusion 1975;15:489-90
  4. Hehmke B, Salzsieder E, Matic GB et al. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther Apher 2000;4:296-302
  5. Lehmann HC, Hartung HP, Meyer Zu, et al. Plasma exchange in neuroimmunological disorders. Part 1. Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006;63:930- 5
  6. Lehmann HC, Hartung HP, Meyer Zu, et al. Plasma exchange in neuroimmunological disorders. Part 2. Treatment of neuromuscular disorders. Arch Neurol 2006;63:1066-71
  7. Aydin Z, Gursu M, Karadag S, et al. Role of plasmapheresis performed in hemodialysis units for the treatment of anti-neutrophilic cytoplasmic antibody-associated systemic vasculitides. Ther Apher Dial 2011;15:493-8
  8. Norda R, Berseus O, Stegmayr B. Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apher Sci 2001;25:33- 41
  9. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for apheresis. J Clin Apher 2007;22:106-75
  10. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher 2000;15:74-128
  11. McLeod BC. Therapeutic plasma exchange in neurologic disorders. In: McLeod BC, Price TH, Weinstein R, editors. Apheresis: principles and practice. Bethasda, MD: AABB Press; 2003. p. 321-44
  12. Karaca S, Kozanoglu I, Goksel BK, et al. Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years. Noro Psikiyatr Ars 2014;51:63-8
  13. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice- Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apheresis 2019; 34:171-354
  14. Seker YT, Hergunsel GO, Bilgi DO, et al. Therapeutic plasmapheresis: an eleven-year clinical experience. The European Res J 2018;4:343-8
  15. Ranganathan L, Menon R, Ramakrishnan N, et